Acorn Wealth Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$530K Buy
8,745
+57
+0.7% +$3.32K 0.15% 133
2025
Q4
$469K Buy
8,688
+90
+1% +$4.33K 0.14% 143
2025
Q3
$388K Buy
8,598
+344
+4% +$16.1K 0.12% 171
2025
Q2
$382K Buy
8,254
+51
+0.6% +$2.5K 0.14% 143
2025
Q1
$500K Buy
8,203
+66
+0.8% +$3.85K 0.21% 104
2024
Q4
$460K Buy
8,137
+40
+0.5% +$2.23K 0.19% 117
2024
Q3
$419K Sell
8,097
-386
-5% -$18.1K 0.18% 113
2024
Q2
$352K Buy
8,483
+1,772
+26% +$79.3K 0.17% 122
2024
Q1
$364K Sell
6,711
-102
-1% -$5.2K 0.19% 112
2023
Q4
$350K Buy
6,813
+234
+4% +$12.3K 0.21% 107
2023
Q3
$382K Buy
6,579
+117
+2% +$7.17K 0.25% 89
2023
Q2
$413K Buy
6,462
+10
+0.2% +$671 0.28% 87
2023
Q1
$447K Sell
6,452
-1
-0% -$71 0.33% 72
2022
Q4
$464K Sell
6,453
-109
-2% -$8.22K 0.36% 68
2022
Q3
$467K Sell
6,562
-482
-7% -$35K 0.38% 63
2022
Q2
$542K Buy
7,044
+156
+2% +$11.9K 0.43% 56
2022
Q1
$503K Buy
6,888
+28
+0.4% +$1.88K 0.35% 70
2021
Q4
$428K Sell
6,860
-196
-3% -$11.5K 0.27% 89
2021
Q3
$417K Buy
7,056
+107
+2% +$7.05K 0.29% 84
2021
Q2
$464K Buy
6,949
+26
+0.4% +$1.7K 0.32% 75
2021
Q1
$437K Buy
6,923
+79
+1% +$4.92K 0.31% 77
2020
Q4
$425K Buy
6,844
+186
+3% +$11.4K 0.33% 69
2020
Q3
$401K Sell
6,658
-239
-3% -$14.4K 0.35% 58
2020
Q2
$406K Buy
6,897
+102
+2% +$6.1K 0.38% 53
2020
Q1
$388K Buy
6,795
+408
+6% +$24.9K 0.43% 49
2019
Q4
$409K Buy
6,387
+11
+0.2% +$630 0.34% 59
2019
Q3
$375K Buy
6,376
+511
+9% +$24K 0.32% 64
2019
Q2
$274K Buy
5,865
+223
+4% +$10.4K 0.25% 86
2019
Q1
$262K Buy
5,642
+19
+0.3% +$946 0.24% 100
2018
Q4
$265K Buy
5,623
+10
+0.2% +$537 0.27% 81
2018
Q3
$292K Sell
5,613
-242
-4% -$14.4K 0.29% 82
2018
Q2
$323K Sell
5,855
-190
-3% -$10.3K 0.28% 68
2018
Q1
$316K Buy
6,045
+7
+0.1% +$450 0.27% 65
2017
Q4
$371K Buy
+6,038
New +$378K 0.34% 53

Other funds holding BMY

Acorn Wealth Advisors's BMY Position: Q1 2026 in Review

Acorn Wealth Advisors increased its Bristol-Myers Squibb (BMY) stake by 0.66% in Q1 2026, buying an estimated $3.32K and bringing the position to 8,745 shares worth $530K. The position accounts for 0.15% of the portfolio, ranked #133.

Acorn Wealth Advisors first reported a position in BMY in Q4 2017 and has held it in 34 quarters since. The position peaked at $542K in Q2 2022. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Acorn Wealth Advisors held 8,745 shares of Bristol-Myers Squibb worth $530K as of Q1 2026.
  • Acorn Wealth Advisors bought 57 Bristol-Myers Squibb shares in Q1 2026, an estimated $3.32K.
  • Bristol-Myers Squibb made up 0.15% of Acorn Wealth Advisors's portfolio in Q1 2026, its #133 holding.
  • Acorn Wealth Advisors first reported a position in Bristol-Myers Squibb in Q4 2017 and has held it in 34 quarters since.
  • Acorn Wealth Advisors's Bristol-Myers Squibb position peaked at $542K in Q2 2022.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Acorn Wealth Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.